ATE408838T1 - Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung - Google Patents
Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankungInfo
- Publication number
- ATE408838T1 ATE408838T1 AT03814521T AT03814521T ATE408838T1 AT E408838 T1 ATE408838 T1 AT E408838T1 AT 03814521 T AT03814521 T AT 03814521T AT 03814521 T AT03814521 T AT 03814521T AT E408838 T1 ATE408838 T1 AT E408838T1
- Authority
- AT
- Austria
- Prior art keywords
- hsc70
- diagnostics
- drug resistant
- tumor disease
- resistant tumor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43801203P | 2003-01-03 | 2003-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE408838T1 true ATE408838T1 (de) | 2008-10-15 |
Family
ID=32713265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03814521T ATE408838T1 (de) | 2003-01-03 | 2003-12-15 | Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7226748B2 (de) |
| EP (1) | EP1588162B1 (de) |
| JP (1) | JP2006512579A (de) |
| AT (1) | ATE408838T1 (de) |
| AU (1) | AU2003300676A1 (de) |
| CA (1) | CA2512513A1 (de) |
| DE (1) | DE60323682D1 (de) |
| WO (1) | WO2004061458A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| US7670604B2 (en) | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| US7550256B2 (en) * | 2002-12-13 | 2009-06-23 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| CA2509902A1 (en) | 2002-12-13 | 2004-07-01 | Aurelium Biopharma Inc. | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| WO2004080819A2 (en) * | 2003-03-14 | 2004-09-23 | Aurelium Biopharma Inc. | Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| DE102004052889A1 (de) * | 2004-11-02 | 2006-05-11 | Ruprecht-Karls-Universität Heidelberg | Screeningverfahren zur Früherkennung des zerebralen Vasospasmus |
| US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
| US20070003559A1 (en) * | 2005-07-01 | 2007-01-04 | Wyeth | Methods of determining pharmacokinetics of targeted therapies |
| WO2007028141A2 (en) * | 2005-08-31 | 2007-03-08 | The Johns Hopkins University | Imaging agents and methods of using same for detecting multidrug resistance in cancer |
| WO2007072221A2 (en) * | 2005-11-10 | 2007-06-28 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
| US20100015643A1 (en) * | 2006-05-19 | 2010-01-21 | Chuwa Tei | Method of quantitative determination of antigen protein and quantitative determination kit therefor |
| GB0705626D0 (en) * | 2007-03-23 | 2007-05-02 | Royal Veterinary College | Method for enhancing sperm survival |
| JP2010538655A (ja) * | 2007-09-12 | 2010-12-16 | アナフォア インコーポレイテッド | 自己免疫疾患についてのｈｓｐ７０に基づく治療 |
| US20090191126A1 (en) * | 2007-11-27 | 2009-07-30 | The Regents Of The University Of California | Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques |
| US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
| CR20190172A (es) * | 2016-09-06 | 2019-06-13 | Incelldx Inc | Methods of detecting per cell pd-l1 expression and uses thereof |
| US12298309B2 (en) | 2016-09-06 | 2025-05-13 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
| US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
| CN114805518B (zh) * | 2022-05-31 | 2023-10-13 | 河南牧业经济学院 | 一种具有免疫调节活性的蛋白wg-sp01 |
| WO2024050560A1 (en) * | 2022-09-02 | 2024-03-07 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating neurodegeneration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720386A (en) | 1976-11-24 | 1988-01-19 | Mccollester Duncan L | Vaccine and method for immunotherapy of neoplastic disease |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US5081154A (en) * | 1984-01-10 | 1992-01-14 | Aktiebolaget Hassle | Metoprolol succinate |
| US5194384A (en) | 1987-04-23 | 1993-03-16 | Bystryn Jean Claude | Method for preparing human meloma vaccine |
| US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
| US5994088A (en) | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
| DE4112999C2 (de) | 1991-04-20 | 1994-11-24 | Klaus Dr Med Ritter | Verfahren und Nachweismittel zum Nachweis einer Infektion mit dem Epstein-Barr Virus |
| US5407653A (en) | 1991-06-26 | 1995-04-18 | Brigham And Women's Hospital | Evaluation of the multidrug resistance phenotype |
| AU5322494A (en) | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| AU724399B2 (en) * | 1995-08-18 | 2000-09-21 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
| JPH107559A (ja) | 1996-06-18 | 1998-01-13 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤 |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US6403308B1 (en) | 1997-04-30 | 2002-06-11 | Mcgill University | Methods for detecting and reversing resistance to macrocyclic lactone compounds |
| AU2903999A (en) | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US6623923B1 (en) | 1998-12-23 | 2003-09-23 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6476193B1 (en) | 1998-10-06 | 2002-11-05 | Curagen Corporation | NLK1 protein and NLK1 protein complexes |
| US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
| US20020177212A1 (en) * | 1999-05-17 | 2002-11-28 | Board Of Regents, The University Of Texas System | Polypeptide that interacts with heat shock proteins |
| JP3829226B2 (ja) | 1999-07-07 | 2006-10-04 | 独立行政法人理化学研究所 | ビメンチンの切断産物に対する抗体 |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6657048B2 (en) | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6730514B2 (en) * | 2000-12-07 | 2004-05-04 | Ranju Ralhan | Stable human oral cancer cell carcinoma cell line |
| HUP0100948A2 (hu) * | 2001-03-02 | 2003-02-28 | Gábor Szabó | Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai |
| BR0208603A (pt) | 2001-04-03 | 2004-03-02 | Merck Patent Gmbh | Marcadores de tumor para carcinoma de células renais |
| US6875849B2 (en) | 2001-05-01 | 2005-04-05 | Arizona Board Of Regents Of Behalf Of The University Of Arizona | Methods of recovering chaperone proteins and complexes thereof |
| US20020198139A1 (en) | 2001-05-17 | 2002-12-26 | Deutschman Clifford S. | Method of preventing acute pulmonary cell injury |
| FR2826780A1 (fr) * | 2001-06-28 | 2003-01-03 | St Microelectronics Sa | Dispositif semi-conducteur a structure hyperfrequence |
| AU2002326361A1 (en) * | 2001-07-16 | 2003-03-03 | Gene Logic, Inc. | Nucleic acid detection assay control genes |
| US20030157081A1 (en) | 2001-10-26 | 2003-08-21 | Bonini Nancy M. | Methods and compositions for suppression of neurodegeneration |
| US6828113B2 (en) | 2002-03-21 | 2004-12-07 | Cornell Research Foundation, Inc. | IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection |
| US7550256B2 (en) * | 2002-12-13 | 2009-06-23 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
-
2003
- 2003-12-15 AT AT03814521T patent/ATE408838T1/de not_active IP Right Cessation
- 2003-12-15 CA CA000000008A patent/CA2512513A1/en not_active Abandoned
- 2003-12-15 JP JP2004564385A patent/JP2006512579A/ja active Pending
- 2003-12-15 EP EP03814521A patent/EP1588162B1/de not_active Expired - Lifetime
- 2003-12-15 DE DE60323682T patent/DE60323682D1/de not_active Expired - Lifetime
- 2003-12-15 AU AU2003300676A patent/AU2003300676A1/en not_active Abandoned
- 2003-12-15 US US10/737,350 patent/US7226748B2/en not_active Expired - Fee Related
- 2003-12-15 WO PCT/IB2003/006416 patent/WO2004061458A2/en not_active Ceased
-
2007
- 2007-05-09 US US11/801,415 patent/US20090004102A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090004102A1 (en) | 2009-01-01 |
| WO2004061458A2 (en) | 2004-07-22 |
| AU2003300676A1 (en) | 2004-07-29 |
| WO2004061458A3 (en) | 2004-11-25 |
| DE60323682D1 (de) | 2008-10-30 |
| EP1588162A2 (de) | 2005-10-26 |
| CA2512513A1 (en) | 2004-07-22 |
| US20040185511A1 (en) | 2004-09-23 |
| JP2006512579A (ja) | 2006-04-13 |
| EP1588162B1 (de) | 2008-09-17 |
| US7226748B2 (en) | 2007-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60323682D1 (de) | Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung | |
| Bentley et al. | Coulomb energy differences between high-spin states in isobaric multiplets | |
| EP1585956A4 (de) | Beurteilung von neuronen im nucleus arcuatus zum screening auf das essverhalten verändernde stoffe | |
| AR096317A2 (es) | Molécula de adn recombinante aislada del adn genómico del evento de maíz mon88017; polinucleótido recombinante y sondas o cebadores recombinantes | |
| DE602005025106D1 (de) | Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen | |
| ATE511649T1 (de) | Verbesserte fret-sonden und ihre verwendung | |
| CY1111486T1 (el) | Μιμητικα αντισωματα (mimetibodies) δεσμευμενα με υποδοχεα μελανοκορτινης, συνθεσεις, μεθοδοι και χρησεις | |
| MX378733B (es) | Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. | |
| DE602006018143D1 (de) | (6-FLU0R-BENZ0Äl, 3ÜDIOXOLYL)-MORPHOLIN-4-YL-METHANONE UND DEREN VERWENDUNG ALS CBl-LIGANDEN | |
| ATE291086T1 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
| EP4372003A4 (de) | Antikörperkombination gegen das regenerierende protein 1alpha aus inselzellen nachweiskit damit | |
| WO2007111938A3 (en) | Inflammation-inhibitory serum factors and uses thereof | |
| WO2007072220A3 (en) | Focused microarray and methods of diagnosing cancer | |
| CY1111809T1 (el) | ΓΟΝΙΔΙΟ Ρi21 ΤΗΣ ΑΣΘΕΝΕΙΑΣ ΠΥΡΙΚΟΥΛΑΡΙΑΣ ΤΗΣ ΟΡΥΖΗΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΟΥ | |
| ATE420101T1 (de) | Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern | |
| ATE456799T1 (de) | Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern | |
| DE50313671D1 (de) | Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening | |
| WO2004055517A3 (en) | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease | |
| ATE451848T1 (de) | Verbesserungen von dampfinjektoren | |
| DE502005002595D1 (de) | Alkyliden-tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer | |
| WO2006089268A3 (en) | Gene and cognate protein profiles and methods to determine connective tissue markers in normal and pathologic conditions | |
| ATE451366T1 (de) | Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente | |
| WO2004097005A3 (en) | Global analysis of transposable elements as molecular markers of the developmental potential of stem cells | |
| Velasquillo et al. | Expression of MIG‐6, WNT‐9A, and WNT‐7B during osteoarthritis | |
| WO2006042005A3 (en) | Global gene expression profiling of circulating tumor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| REN | Ceased due to non-payment of the annual fee |